Biomarkers · Cardiac & Hemodynamics

Mid-Regional Pro-Adrenomedullin (MR-proADM)

Lower values go with lower risk of death. No risk curve catalogued yet.

Published risk of death2.37×contrast not reported (95% CI 1.72–3.26) · KORA F4 population-based cohort, Germany, n=1551 aged 56.9±12.9 years

What studies found when this marker was changed

They describe what happened in those study groups, not a recommendation. See all catalogued interventions.

Measured changes in MR-proADM, study by study

2 effects with a numeric size, each from one study arm: the dot is the reported change, the line its 95% interval where one was given. Green points move the marker the way lower risk of death lies; amber the other way. Study results in the groups studied, not predictions for a person.

Each row is one study: what was changed, the effect it reported on this marker, and the source.
Type	Intervention	Reported effect	Evidence	Source
pharmacologic	Liraglutide 1.8 mg daily vs placebo for 12 weeks in a crossover trial of people with type 2 diabetes and albuminuria	MR-proADM was 4% (95% CI 0 to 8) lower after liraglutide vs placebo at 12 weeks; n=27	RCT	von Scholten BJ, et al. Diabetes Obes Metab. 2017;19(6):901-905.

Things that worsen it

Each row is one study: what was changed, the effect it reported on this marker, and the source.
Type	Condition or exposure	Reported effect	Evidence	Source
pharmacologic	Sacubitril/valsartan for 12 weeks in heart failure (HFrEF and HFpEF)	MR-proADM rose 49% in HFrEF (60% in HFpEF) at 12 weeks vs +2% with valsartan	RCT	Myhre PL, Liu Y, Kulac IJ, et al. Eur J Heart Fail. 2023.

What else moves this marker

They describe those study groups, not an individual, and an association is not a cause.

Diseases and conditions

Each row is one study: what it compared and the change it reported in this marker.
What	Effect on the marker	Comparison · population	Source
↑ COVID-19, critical illness · critically ill vs non-critically ill COVID-19 patients	+0.71 nmol/L (95% CI 0.22 to 1.2)	critically ill vs non-critically ill · 27 studies, 2213 COVID-19 patients (endothelial biomarkers by severity)	meta analysis · PMID 34702152
↑ COVID-19, fatal course · hospitalised COVID-19 non-survivors vs survivors	+0.78 nmol/L (95% CI 0.64 to 0.92)	non-survivors vs survivors · 14 studies of hospitalised COVID-19 patients	meta analysis · PMID 36607317
↑ COVID-19, poor outcome · COVID-19 patients with poor vs good outcome	SMD +1.52 (95% CI 1.35 to 1.68)	poor outcome vs good outcome · 74 studies, 7668 COVID-19 patients	meta analysis · PMID 36943015

Genetic predisposition

Each row is one study: what it compared and the change it reported in this marker.
What	Effect on the marker	Comparison · population	Source
↕ Common genetic variants (KLKB1 rs4253238, F12 rs2731672, ADM rs2957692) · total phenotypic variance explained by identified variants	+7.2%	proportion of MR-proADM variance explained · 3444 European-ancestry discovery participants plus 3230 follow-up	gwas · PMID 23381795

Sources

Gar C, Thorand B, Herder C, et al. Association of circulating MR-proADM with all-cause and cardiovascular mortality in the general population: Results from the KORA F4 cohort study. PLOS One. 2022;17(1):e0262330.